Published in Br J Cancer on October 01, 1998
Mechanisms underlying losses of heterozygosity in human colorectal cancers. Proc Natl Acad Sci U S A (2001) 1.68
Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol (2003) 1.11
DNA copy number changes in thyroid carcinoma. Am J Pathol (1999) 1.09
Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol (2001) 0.87
Evaluation of the PAX8/PPARG translocation in follicular thyroid cancer with a 4-color reverse-transcription PCR assay and automated high-resolution fragment analysis. Clin Chem (2010) 0.85
DNA copy number variations characterize benign and malignant thyroid tumors. J Clin Endocrinol Metab (2013) 0.79
Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma. Oncotarget (2016) 0.78
Genomic differences in benign and malignant follicular thyroid tumours using 1-Mb array-comparative genomic hybridisation. Eur Arch Otorhinolaryngol (2012) 0.76
DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol (1998) 4.61
Classification and prognosis of thyroid carcinoma. A study of 885 cases observed in a thirty year period. Am J Surg (1961) 4.16
The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer (1989) 2.52
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet (1994) 2.28
Detection of multiple gains and losses of genetic material in ten glioma cell lines by comparative genomic hybridization. Genes Chromosomes Cancer (1995) 1.25
Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer (1997) 1.19
Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancers. J Clin Invest (1991) 1.13
Loss of heterozygosity at chromosome regions 22q11-12 and 11p15.5 in renal rhabdoid tumors. Genes Chromosomes Cancer (1996) 1.12
DNA aneuploidy in adenomas of endocrine organs. Am J Pathol (1988) 1.11
Optimization of comparative genomic hybridization using fluorochrome conjugated to dCTP and dUTP nucleotides. Lab Invest (1997) 1.09
Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab (1997) 1.01
Chromosomal changes in thyroid tumors. Relation with DNA content, karyotypic features, and clinical data. Cancer Genet Cytogenet (1990) 0.89
Chromosome studies in thyroid neoplasia. Cancer (1989) 0.84
Thyroid nodular hyperplasia: chromosomal studies in 14 cases. Cancer Genet Cytogenet (1993) 0.84
Abnormalities of chromosome 22 in meningiomas and confirmation of the origin of a dicentric 22 by in situ hybridization. Cancer Genet Cytogenet (1992) 0.84
Cytogenetics of thyroid follicular adenomas. Cancer Genet Cytogenet (1990) 0.83
Deletion of 3p25-->pter in a primary follicular thyroid carcinoma and its metastasis. Genes Chromosomes Cancer (1993) 0.83
Detection of numerical alterations for chromosomes 7 and 12 in benign thyroid lesions by in situ hybridization. Histological implications. Am J Pathol (1995) 0.82
Chromosomal aberrations in follicular thyroid carcinoma. Case report of a primary tumor and its metastasis. Cancer Genet Cytogenet (1991) 0.81
A characteristic sequence of trisomies starting with trisomy 7 in benign thyroid tumors. Hum Genet (1994) 0.80
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol (1998) 4.61
Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet (1997) 4.27
Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol (2005) 4.00
Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer (1985) 3.69
Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med (1990) 3.21
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology (2000) 3.01
DNA copy number losses in human neoplasms. Am J Pathol (1999) 2.73
Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. J Nucl Med (1993) 2.66
Increased expression of high mobility group A proteins in lung cancer. J Pathol (2006) 2.39
Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol (2009) 2.35
A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol (1992) 2.34
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res (1998) 2.33
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res (1995) 2.31
Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res (1999) 2.18
Oligonucleotide array-CGH reveals cryptic gene copy number alterations in karyotypically normal acute myeloid leukemia. Leukemia (2007) 2.11
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol (1992) 2.10
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res (1996) 1.99
Familial aniridia and translocation t(4;11)(q22;p13) without Wilms' tumor. Hum Genet (1983) 1.83
Aggressiveness of breast cancers found with and without screening. BMJ (1992) 1.83
Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost (1998) 1.80
Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology (2001) 1.74
Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci U S A (2000) 1.69
Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer (1999) 1.67
DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer (1998) 1.66
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer (2009) 1.62
Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol (1998) 1.61
Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogenet (2000) 1.59
Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med (1997) 1.58
Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci (2001) 1.57
The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up. Br J Cancer (1989) 1.55
Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet (2001) 1.55
A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood (1997) 1.51
DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res (2000) 1.51
Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood (1996) 1.49
BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A (2001) 1.48
Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer. Scand J Clin Lab Invest (2001) 1.47
Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer (1997) 1.46
Post-mastectomy radiotherapy in pT3N0M0 breast cancer: is it needed? Radiother Oncol (1999) 1.44
High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer (1998) 1.40
Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer (1997) 1.40
Colony formation by megakaryocyte progenitors in myelodysplatic syndromes. Eur J Haematol (1989) 1.39
Financial compensation for radiotherapy-related adverse events in a judicial system where proof of medical negligence is not required. Int J Radiat Oncol Biol Phys (2001) 1.39
Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res (1997) 1.38
The inheritance of fragile sites: apparent absence of fra(2)(q13) in the parents of three unrelated probands. J Med Genet (1987) 1.38
Immunophenotyping and molecular cytogenetics. J Histochem Cytochem (1992) 1.38
Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial. Ann Oncol (2003) 1.38
Reliability of histopathologic diagnosis of malignant lymphoma. Ann Clin Res (1973) 1.35
DNA copy number changes in diffuse large B-cell lymphoma--comparative genomic hybridization study. Blood (1996) 1.34
Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res (1995) 1.34
Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol (2001) 1.33
Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. J Clin Oncol (2001) 1.33
Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol (2011) 1.28
Chronic lymphocytic leukaemia patients have a high risk of Merkel-cell polyomavirus DNA-positive Merkel-cell carcinoma. Br J Cancer (2009) 1.26
DNA copy number amplification profiling of human neoplasms. Oncogene (2006) 1.25
CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene (2012) 1.23
Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer (2001) 1.23
Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut (2004) 1.22
A practical metaphase marker of the inactive X chromosome. Am J Hum Genet (1986) 1.20
Gene expression profiling of ameloblastoma and human tooth germ by means of a cDNA microarray. J Dent Res (2002) 1.19
Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer (1997) 1.19
BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood (1997) 1.18
Glycogen-rich clear-cell carcinoma of the breast: a clinicopathologic and flow cytometric study. Hum Pathol (1991) 1.16
Cytogenetic study of 249 consecutive patients examined for a bone tumor. Cancer Genet Cytogenet (1993) 1.16
Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion. Leukemia (2001) 1.16
Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer (2001) 1.15
Transforming and membrane proteins. Nature (1988) 1.15
DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer (1999) 1.15
Recurrent gains of 1q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer (1997) 1.14
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer (2007) 1.13
Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol (1997) 1.13
Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res (1998) 1.13
Pallister-Killian syndrome: cytogenetic and molecular studies. Clin Genet (1987) 1.13
Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. Int J Radiat Oncol Biol Phys (2000) 1.13
Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: a combined cytogenetic and comparative genomic hybridization study. Genes Chromosomes Cancer (1996) 1.13
Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer (2002) 1.13
Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer (2000) 1.12
Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer (1994) 1.12
p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer (1995) 1.12
Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand A (1978) 1.11
Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker. Am J Pathol (1997) 1.10
Chromosome pulverization in blood diseases. Hereditas (1981) 1.10
Immunohistochemical spectrum of malignant melanoma. The common presence of keratins. Lab Invest (1989) 1.10
Optimization of comparative genomic hybridization using fluorochrome conjugated to dCTP and dUTP nucleotides. Lab Invest (1997) 1.09
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer (2004) 1.09
DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet Cytogenet (2000) 1.09
DNA copy number changes in thyroid carcinoma. Am J Pathol (1999) 1.09
Different patterns of DNA copy number changes in gastrointestinal stromal tumors, leiomyomas, and schwannomas. Hum Pathol (1998) 1.08